Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Abstract The SARS-CoV-2 Omicron variant exhibits striking immune evasion and is
spreading rapidly worldwide. Understanding the structural basis of the high transmissibility …

Abstract The SARS-CoV-2 Delta variant is currently the dominant circulating strain in the
world. Uncovering the structural basis of the enhanced transmission and altered immune …

The emergence of SARS-CoV-2 Kappa and Beta variants with enhanced transmissibility
and resistance to neutralizing antibodies has created new challenges for the control of the …

Broadly neutralizing antibodies are an important treatment for individuals with coronavirus
disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 …

Spike (S) protein is the primary antigenic target for neutralization and vaccine development
for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It decorates the …

Broad-spectrum anti-SARS-CoV-2 strategies that can inhibit the infection of wild-type and
mutant strains would alleviate their threats to global public health. Here, we propose an …

SARS-CoV-2 is a novel β-coronavirus that caused the COVID-19 pandemic disease, which
spread rapidly, infecting more than 134 million people, and killing almost 2.9 million thus far …